Ozempic, Wegovy-maker hires lobbying firm to push for Medicare coverage
The blockbuster weight loss drugs’ access to a key market — older Americans — is limited, as Medicare is banned from covering weight loss drugs as part of the Part D program.
The blockbuster weight loss drugs’ access to a key market — older Americans — is limited, as Medicare is banned from covering weight loss drugs as part of the Part D program.
The blockbuster weight loss drugs’ access to a key market — older Americans — is limited, as Medicare is banned from covering weight loss drugs as part of the Part D program.
The blockbuster weight loss drugs’ access to a key market — older Americans — is limited, as Medicare is banned from covering weight loss drugs as part of the Part D program.
The blockbuster weight loss drugs’ access to a key market — older Americans — is limited, as Medicare is banned from covering weight loss drugs as part of the Part D program.
The blockbuster weight loss drugs’ access to a key market — older Americans — is limited, as Medicare is banned from covering weight loss drugs as part of the Part D program.
The blockbuster weight loss drugs’ access to a key market — older Americans — is limited, as Medicare is banned from covering weight loss drugs as part of the Part D program.
The blockbuster weight loss drugs’ access to a key market — older Americans — is limited, as Medicare is banned from covering weight loss drugs as part of the Part D program.
In its suit, the drug giant claims that Medicare negotiation program is unconstitutional
Sanders’ well-chronicled antagonism toward lobbyists has some concerned they’ll be unable to blunt criticism of their clients’ profits or corporate executive salaries.
Sanders’ well-chronicled antagonism toward lobbyists has some concerned they’ll be unable to blunt criticism of their clients’ profits or corporate executive salaries.
The departure of Michelle McMurry-Heath comes just as the Biden administration is poised to begin implementing key drug pricing provisions and the balance of power could shift in Congress.
The departure of Michelle McMurry-Heath comes just as the Biden administration is poised to begin implementing key drug pricing provisions and the balance of power could shift in Congress.
The departure of Michelle McMurry-Heath comes just as the Biden administration is poised to begin implementing key drug pricing provisions and the balance of power could shift in Congress.
The departure of Michelle McMurry-Heath comes just as the Biden administration is poised to begin implementing key drug pricing provisions and the balance of power could shift in Congress.
The departure of Michelle McMurry-Heath comes just as the Biden administration is poised to begin implementing key drug pricing provisions and the balance of power could shift in Congress.
The departure of Michelle McMurry-Heath comes just as the Biden administration is poised to begin implementing key drug pricing provisions and the balance of power could shift in Congress.
Lawmakers introduced a measure mirroring a proposal written by one of the nation’s largest dialysis providers.
Lawmakers introduced a measure mirroring a proposal written by one of the nation’s largest dialysis providers.
Lawmakers introduced a measure mirroring a proposal written by one of the nation’s largest dialysis providers.
PhRMA CEO Steve Ubl says the group is still fighting hard against the drug pricing provisions, but is making contingency plans — and promises — should reconciliation become law.
PhRMA CEO Steve Ubl says the group is still fighting hard against the drug pricing provisions, but is making contingency plans — and promises — should reconciliation become law.
PhRMA CEO Steve Ubl says the group is still fighting hard against the drug pricing provisions, but is making contingency plans — and promises — should reconciliation become law.
PhRMA CEO Steve Ubl says the group is still fighting hard against the drug pricing provisions, but is making contingency plans — and promises — should reconciliation become law.
The package would permit negotiation on drug pricing in Medicare and appears to have a path to passage.
The package would permit negotiation on drug pricing in Medicare and appears to have a path to passage.
The package would permit negotiation on drug pricing in Medicare and appears to have a path to passage.
The package would permit negotiation on drug pricing in Medicare and appears to have a path to passage.
The package would permit negotiation on drug pricing in Medicare and appears to have a path to passage.
They are avoiding the fallout from the Roe decision to ensure eased rules are extended beyond the pandemic.
They are avoiding the fallout from the Roe decision to ensure eased rules are extended beyond the pandemic.